Drug firm GSK Pharmaceuticals Ltd on Thursday (November 6) reported a 2% year-on-year increase in net profit to ₹257.5 crore for the quarter ended September 2025, compared with ₹252.5 crore in the same period last year. Revenue from operations declined 3% year-on-year to ₹979.9 crore from ₹1,010.7 crore.

Earnings before interest, tax, depreciation, and amortisation (EBITDA) grew 4.5% year-on-year to ₹336.2 crore, against ₹321.5 crore in the corresponding quarter of the previous year. The company’s EBITDA margin improved to 34.4%, up from 31.8% a year ago, supported by improved gross margins and operating leverage.

The company reported steady growth across its key portfolios during the quarter, with its newly launched Oncology portfolio off to a strong start. While topline growth was mu

See Full Page